Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

On January 5, 2022 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually on January 10-13, 2022 (Press release, Leap Therapeutics, JAN 5, 2022, View Source [SID1234598256]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on Monday, January 10 at 7:00 a.m. Eastern Time and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.